Safety and Efficacy (Phase II) Study of Concurrent Cetuximab Plus Conformal Thoracic Radiotherapy in (Poor Prognosis) Patients With Inoperable or Unresectable, Locally Advanced Non-Small Cell Lung Cancer (LA - NSCLC).
Phase of Trial: Phase II
Latest Information Update: 12 Oct 2015
At a glance
- Drugs Cetuximab (Primary) ; Docetaxel
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 07 Oct 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 22 Jun 2015 According to the ClinicalTrials.gov record, planned end date changed from 1 Jul 2015 to 1 Jun 2016.
- 15 Jan 2015 Planned End Date changed from 1 Apr 2015 to 1 Jul 2015 as reported by ClinicalTrials.gov.